Case Report

Cinacalcet in the Treatment of Intractable Hypercalcemia Following Two Neck Exploration Surgeries for Primary Hyperparathyroidism

Authors: Hema Padmanabhan, MD, FACP

Abstract

Primary hyperparathyroidism is commonly due to a single, sporadic parathyroid adenoma, and surgery is considered the treatment of choice based on guidelines established by the National Institutes of Health consensus panel. While there is no established medical therapy for this condition, pharmacotherapy with agents such as cinacalcet could be a preferred alternative in a subset of patients with persistent hypercalcemia after one or more surgical interventions.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and Disorders of Mineral Metabolism, in Larsen PR, Kronenberg HM, Melmed S, et al (eds): Williams Textbook of Endocrinology. Philadelphia, PA, Saunders, 2003, ed 10, pp 1303–1371.
 
2. Farford B, Presutti RJ, Moraghan TJ. Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc 2007;62:351–355.
 
3. Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007;37:915–922.
 
4. Byrnes CA, Shepler BM. Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis. Pharmacotherapy 2005;25:709–716.
 
5. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis; a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800–807.
 
6. Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr 2006;16:253–258.
 
7. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentrations in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007;92:3803–3808.
 
8. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644–5649.
 
9. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135–141.